Cohorts without frontiers : RaDiCo commits at the heart of European projects
RaDiCo is open to any opportunity of international collaboration on Rare Diseases. We have the will to be committed to European projects, particularly those belonging to the “Horizon 2020”, the European program for research and innovation, and of those of the Department of health and consumers of the European Commission. RaDiCo's team otherwise pays a particular attention to cooperation, skill translation and strengthening of capacities in developing countries. We also aim at supporting the implementation of national programs in any country that would need it, by sharing our expertise in database management and implementation of national cohorts on rare diseases. Beyond its own projects, RaDiCo promotes the commitment of French actors to European and international projects needing the implementation of borderless cohorts. We advise and support you for the setting up of propositions and for the management of your programs in this field.
For more information on international projects and on funding opportunities, please click here.
About RaDiCo
RaDiCo program aims at endowing France with large epidemiological instruments or "cohorts" in the field of rare diseases. These cohorts are designed to improve the understanding of health determinants of rare diseases and ultimately, to the development of new therapeutic strategies. RaDiCo is coordinated by the French Institute on Health and Medical Research (Inserm). It is funded by the French Health Ministry in the framework of the so-called "Investissements d'Avenir" funding scheme. Based in Paris, RaDiCo offers a clinical research and services platform for the translational research on rare diseases.
RaDiCo promotes public private partnerships
By promoting public-private-partnerships, RaDiCo aims at accelerating discoveries on rare diseases. We propose models of public-private partnerships designed to take advantage of the knowledge and data generated by rare diseases cohorts. Whatever you are a biotech company, a big pharma or a specialist in new information technologies, we are your partner for the access to resources stemming from national and international cohorts in this field.